Nabriva Therapeutics plc

NBRVF

0.00010.00% ( 0.0000 )

Delay Trading: Oct 9, 09:30:00 (EDT)

Current ValuationThe current P/E ratio is 0.00, within the reasonable range, cheaper than 27.26% of the time in the past 10 years, and the industry ranks 52/255, the industry Median -1.32.

-0xP/E

Stock price$0.00Earnings per share$-8.52

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

0285684112

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x20x40x60x80x100x

P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company	-56.03x	148.12%	$58.51B
BAYRYUSBayer	-23.51x	--	$47.43B
BAYZFUSBayer Aktiengesellschaft	-23.37x	--	$47.16B
VTRSUSViatris	-48.77x	107.75%	$20.03B
ELANUSElanco Animal Health	-56.59x	129.36%	$11.26B
AXSMUSAxsome Therap	-46.49x	26.15%	$8.91B
VREOFUSVIREO GROWTH INC	-130.38x	--	$8.75B
CURLFUSCuraleaf Holdings, Inc.	-138.89x	--	$7.23B
BLTEUSBelite Bio	-60.00x	29.87%	$6.14B
MANEUSVeraDermics	-50.73x	97.44%	$5.29B
DFTXUSDefinium Therapeutics	-12.98x	53.61%	$4.59B
EWTXUSEdgewise Therapeutics	-21.60x	137.29%	$4.26B
RGCUSRegencell Bioscience	-323.06x	--	$3.78B
AMLXUSAmylyx Pharmaceuticals	-22.45x	1.76%	$3.41B
TARSUSTarsus Pharmaceuticals	-68.19x	205.82%	$3.17B
ELVNUSEnliven Therapeutics	-28.10x	6.39%	$2.98B
MBXUSMBX Biosciences	-24.59x	31.12%	$2.56B
SUPNUSSupernus Pharma	-22.29x	70.59%	$2.45B
BHCUSBausch Health	-2.06x	305.55%	$2.26B
PHVSUSPharvaris BV	-11.01x	10.73%	$2.18B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.